Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

ClinicalTrials.gov ID: NCT01392547

Public ClinicalTrials.gov record NCT01392547. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors

Study identification

NCT ID
NCT01392547
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
72 participants

Conditions and interventions

Interventions

  • vatreptacog alfa (activated) Drug
  • eptacog alfa (activated) Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012
Last update posted
May 14, 2017

2011 – 2012

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Novo Nordisk Clinical Trial Call Center Tucson Arizona 85724-0001
Novo Nordisk Clinical Trial Call Center Los Angeles California 90007
Novo Nordisk Clinical Trial Call Center Los Angeles California 90027
Novo Nordisk Clinical Trial Call Center Orange California 92868
Novo Nordisk Clinical Trial Call Center Aurora Colorado 80045
Novo Nordisk Clinical Trial Call Center Tampa Florida 33607
Novo Nordisk Clinical Trial Call Center Atlanta Georgia 30322
Novo Nordisk Clinical Trial Call Center Augusta Georgia 30912
Novo Nordisk Clinical Trial Call Center Iowa City Iowa 52242
Novo Nordisk Clinical Trial Call Center Boston Massachusetts 02115
Novo Nordisk Clinical Trial Call Center Detroit Michigan 48202-2608
Novo Nordisk Clinical Trial Call Center Brooklyn New York 11219
Novo Nordisk Clinical Trial Call Center Portland Oregon 97239
Novo Nordisk Clinical Trial Call Center Richmond Virginia 23219

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01392547, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 14, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01392547 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →